These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18719964)

  • 1. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer.
    Holm N; Byrnes K; Johnson L; Abreo F; Sehon K; Alley J; Meschonat C; Md QC; Li BD
    Ann Surg Oncol; 2008 Nov; 15(11):3207-15. PubMed ID: 18719964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer.
    Wolfort R; de Benedetti A; Nuthalapaty S; Yu H; Chu QD; Li BD
    Surgery; 2006 Aug; 140(2):161-9. PubMed ID: 16904965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.
    Byrnes KW; DeBenedetti A; Holm NT; Luke J; Nunez J; Chu QD; Meschonat C; Abreo F; Johnson LW; Li BD
    J Am Coll Surg; 2007 May; 204(5):925-33; discussion 933-4. PubMed ID: 17481512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer.
    McClusky DR; Chu Q; Yu H; Debenedetti A; Johnson LW; Meschonat C; Turnage R; McDonald JC; Abreo F; Li BD
    Ann Surg; 2005 Oct; 242(4):584-90; discussion 590-2. PubMed ID: 16192819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of eukaryotic initiation factor 4E is correlated with increased risk for systemic dissemination in node-positive breast cancer patients.
    Yin X; Kim RH; Sun G; Miller JK; Li BD
    J Am Coll Surg; 2014 Apr; 218(4):663-71. PubMed ID: 24491247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of eIF4E reduction after neoadjuvant therapy in breast cancer.
    Hiller DJ; Chu Q; Meschonat C; Panu L; Burton G; Li BD
    J Surg Res; 2009 Oct; 156(2):265-9. PubMed ID: 19665145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma.
    Li BD; Liu L; Dawson M; De Benedetti A
    Cancer; 1997 Jun; 79(12):2385-90. PubMed ID: 9191527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.
    Chu QD; Panu L; Holm NT; Li BD; Johnson LW; Zhang S
    J Surg Res; 2010 Apr; 159(2):689-95. PubMed ID: 19500800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma.
    Wang R; Geng J; Wang JH; Chu XY; Geng HC; Chen LB
    Lung Cancer; 2009 Nov; 66(2):237-44. PubMed ID: 19261348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome.
    Chen CN; Hsieh FJ; Cheng YM; Lee PH; Chang KJ
    J Surg Oncol; 2004 Apr; 86(1):22-7. PubMed ID: 15048676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study.
    Mizell J; Smith M; Li BD; Ampil F; Chu QD
    Ann Surg Oncol; 2009 Oct; 16(10):2711-6. PubMed ID: 19593633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome.
    Li BD; Gruner JS; Abreo F; Johnson LW; Yu H; Nawas S; McDonald JC; DeBenedetti A
    Ann Surg; 2002 May; 235(5):732-8; discussion 738-9. PubMed ID: 11981220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
    Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
    Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor.
    Sorrells DL; Meschonat C; Black D; Li BD
    J Surg Res; 1999 Jul; 85(1):37-42. PubMed ID: 10383835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
    Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
    Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].
    Fodor J
    Magy Onkol; 2007; 51(2):127-31. PubMed ID: 17660868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer.
    Salehi Z; Mashayekhi F
    Clin Biochem; 2006 Apr; 39(4):404-9. PubMed ID: 16375881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.